Adimab LLC-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Adimab LLC - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011812
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Adimab LLC (Adimab) is an antibody discovery technology provider that offers antibody discovery and optimization platform. The company discovers antibodies for a range of disease areas including oncology, immunomodulation, neuroscience and pain, inflammation, cardiovascular and metabolic disease, and infectious disease. Its platform delivers and optimizes various panels of therapeutically relevant antibodies that meet the standards for affinity, epitope coverage, species cross reactivity and developability. The company has completed discovery programs in various protein classes such as serum proteins, TNF superfamily receptors, ECM adhesion receptors, enzymes, natural peptides, cytokines, ion channels and GPCRs. Adimab is headquartered in Lebanon, New Hampshire, the US.

Adimab LLC – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 10
Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Adimab LLC, Pharmaceuticals & Healthcare, Deal Details 13
Venture Financing 13
Adimab Raises US$13.8 Million In Series F Financing 13
Partnerships 15
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 15
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 16
iTeos Therapeutics Enters into Agreement with Adimab 17
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 18
Adimab Enters into Research Agreement with Kite Pharma 19
Adimab Enters into Discovery Agreement with Celgene 20
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 21
Adimab Enters into Agreement with Acceleron Pharma 22
Adimab Enters into Agreement with Oncothyreon 23
Adimab Enters into Agreement with Surface Oncology 24
Adimab Enters into Agreement with Potenza Therapeutics 25
Five Prime Therapeutics Enters Into Research Agreement With Adimab 26
Jounce Therapeutics Enters Into Research Agreement With Adimab 27
Alector Enters Into Research Agreement With Adimab 28
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 29
Adimab Expands Agreement with Innovent Biologics 30
GlaxoSmithKline Expands its Partnership with Adimab 31
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 32
Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 33
Adimab Enters Into Co-Development Agreement With Gilead Sciences 34
Adimab Enters Into Co-Development Agreement With Biogen Idec 35
Adimab Enters Into Co-Development Agreement With Novo Nordisk 36
Arsanis Enters into Agreement with Adimab 37
Licensing Agreements 38
Eli Lilly Enters into Licensing Agreement with Adimab 38
Arsanis Enters into Licensing Agreement with Adimab 39
Kite Pharma Exercises Option for Licensing Agreement with Adimab 40
Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 41
Adimab Enters into Licensing Agreement with Merck 42
Mersana Therapeutics Amends its Licensing Agreement with Adimab 43
Adimab Enters Into Licensing Agreement With Novo Nordisk 44
Biogen Idec Enters Into Licensing Agreement With Adimab 45
GlaxoSmithKline Enters Into Licensing Agreement With Adimab 47
Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 48
Adimab LLC – Key Competitors 49
Adimab LLC – Key Employees 50
Adimab LLC – Locations And Subsidiaries 51
Head Office 51
Recent Developments 52
Product News 52
04/25/2016: Adimab Expands Bispecific Antibody Offering with Novel CD3 Program 52
Feb 18, 2016: Adimab Scientists Report the Isolation of Highly Potent Anti-Ebola Virus Antibodies from Recent Zaire Outbreak 53
Other Significant Developments 54
Jan 10, 2017: Adimab Provides Annual Update on 2016 Partnerships and Milestones 54
Apr 25, 2016: Adimab Expands Bispecific Antibody Offering with Novel CD3 Program 55
Jan 11, 2016: Adimab Provides Update on Recent Partnerships and Milestones 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Adimab LLC, Pharmaceuticals & Healthcare, Key Facts 2
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 7
Adimab LLC, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 8
Adimab LLC, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 9
Adimab LLC, Deals By Therapy Area, 2011 to YTD 2017 10
Adimab LLC, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 11
Adimab Raises US$13.8 Million In Series F Financing 13
Adimab Enters into Drug Discovery Agreement with Kodiak Sciences 15
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 16
iTeos Therapeutics Enters into Agreement with Adimab 17
Adimab Enters into Agreement with The University of Texas MD Anderson Cancer Center and Memorial Sloan Kettering Cancer Center 18
Adimab Enters into Research Agreement with Kite Pharma 19
Adimab Enters into Discovery Agreement with Celgene 20
Adimab Enters into Agreement with Sanofi for Bispecific Antibody 21
Adimab Enters into Agreement with Acceleron Pharma 22
Adimab Enters into Agreement with Oncothyreon 23
Adimab Enters into Agreement with Surface Oncology 24
Adimab Enters into Agreement with Potenza Therapeutics 25
Five Prime Therapeutics Enters Into Research Agreement With Adimab 26
Jounce Therapeutics Enters Into Research Agreement With Adimab 27
Alector Enters Into Research Agreement With Adimab 28
Adimab Enters Into Agreement With Celgene To Discover Therapeutic Antibodies 29
Adimab Expands Agreement with Innovent Biologics 30
GlaxoSmithKline Expands its Partnership with Adimab 31
Adimab Expands Collaboration With Merck To Discover Human Antibody Candidates 32
Adimab Enters Into Antibody Discovery Agreement With Kyowa Hakko Kirin 33
Adimab Enters Into Co-Development Agreement With Gilead Sciences 34
Adimab Enters Into Co-Development Agreement With Biogen Idec 35
Adimab Enters Into Co-Development Agreement With Novo Nordisk 36
Arsanis Enters into Agreement with Adimab 37
Eli Lilly Enters into Licensing Agreement with Adimab 38
Arsanis Enters into Licensing Agreement with Adimab 39
Kite Pharma Exercises Option for Licensing Agreement with Adimab 40
Jounce Therapeutics Exercises Option for Licensing Agreement with Adimab 41
Adimab Enters into Licensing Agreement with Merck 42
Mersana Therapeutics Amends its Licensing Agreement with Adimab 43
Adimab Enters Into Licensing Agreement With Novo Nordisk 44
Biogen Idec Enters Into Licensing Agreement With Adimab 45
GlaxoSmithKline Enters Into Licensing Agreement With Adimab 47
Eli Lilly Exercises Option for Licensing Agreement with Adimab for Multiple Bispecific Antibodies 48
Adimab LLC, Key Competitors 49
Adimab LLC, Key Employees 50

★海外企業調査レポート[Adimab LLC-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Novartis Pharmaceuticals Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Novartis Pharmaceuticals Corp (Novartis), a subsidiary of Novartis AG, is a manufacturer of prescription drugs. The company portfolio includes cardio metabolic, ophthalmology, respiratory, neuroscience, immunology and dermatology, oncology, call and gene therapy. It provides medicines such a …
  • MAMEE-Double Decker (M) Sdn Bhd:企業の戦略的SWOT分析
    MAMEE-Double Decker (M) Sdn Bhd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Matthews International Corp (MATW):企業の財務・戦略的SWOT分析
    Matthews International Corp (MATW) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Aarti Industries Ltd (AARTIIND):企業の財務・戦略的SWOT分析
    Summary Aarti Industries Ltd (Aarti Industries) is a chemical company that manufactures and markets benzene based basic and intermediate chemicals. It offers chemicals, pharma products and surfactants including rubber chemicals, dyes and pigment intermediates; surfactant intermediates, pharmaceutica …
  • Scotiabank Private Banking:企業の戦略・SWOT・財務分析
    Scotiabank Private Banking - Strategy, SWOT and Corporate Finance Report Summary Scotiabank Private Banking - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • The Williams Companies, Inc.:企業の戦略・SWOT・財務分析
    The Williams Companies, Inc. - Strategy, SWOT and Corporate Finance Report Summary The Williams Companies, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Flynn Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Flynn Pharma Ltd (Flynn Pharma) is a pharmaceutical company that manufactures and markets barbiturate products, and oral and injectable antibiotics. The company’s products include cefuroxime, circadin, distaclor, keflex, medikinet tablets, medikinet XL capsules, nebcin, nizatidine, phenytoin …
  • Centre for Drug Design and Discovery:製薬・医療:M&Aディール及び事業提携情報
    Summary Centre for Drug Design and Discovery (CD3) is a biomedical research institution that discovers new small molecule drugs. The institution operates as an investment fund and technology transfer platform to promote the discovery and development of medicines for all kinds of diseases. It provide …
  • Gilbane Inc:企業の戦略・SWOT・財務分析
    Gilbane Inc - Strategy, SWOT and Corporate Finance Report Summary Gilbane Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Shoprite Holdings Ltd:企業の戦略・SWOT・財務情報
    Shoprite Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Shoprite Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • OGK-2 (OGKB):企業の財務・戦略的SWOT分析
    OGK-2 (OGKB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pote …
  • Merck KGaA (MRK)-医療機器分野:企業M&A・提携分析
    Summary Merck KGaA (Merck), a subsidiary of E. Merck KG, is a pharmaceutical and chemical company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis, and infertility and over-the-counter products for colds and pain; and develops liquid crystal mixtures, O …
  • United Technologies Corp (UTX):企業の財務・戦略的SWOT分析
    United Technologies Corp (UTX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Liechtensteinische Landesbank Ag:企業の戦略・SWOT・財務分析
    Liechtensteinische Landesbank Ag - Strategy, SWOT and Corporate Finance Report Summary Liechtensteinische Landesbank Ag - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Central Glass Co Ltd (4044):企業の財務・戦略的SWOT分析
    Central Glass Co Ltd (4044) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Evonik Industries AG (EVK):企業の財務・戦略的SWOT分析
    Evonik Industries AG (EVK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Rowan Companies plc:企業の戦略・SWOT・財務分析
    Rowan Companies plc - Strategy, SWOT and Corporate Finance Report Summary Rowan Companies plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Meyer Burger Technology AG (MBTN):企業の財務・戦略的SWOT分析
    Meyer Burger Technology AG (MBTN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Sumitomo Seika Chemicals Co Ltd (4008):企業の財務・戦略的SWOT分析
    Sumitomo Seika Chemicals Co Ltd (4008) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • ClearStream Energy Services Inc:企業の戦略・SWOT・財務情報
    ClearStream Energy Services Inc - Strategy, SWOT and Corporate Finance Report Summary ClearStream Energy Services Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆